

Does N-Acetylcysteine (Parvolex®) prophylaxis reduce the incidence of renal impairment after onpump Coronary Artery Bypass Graft surgery? A prospective randomised controlled trial

Submission date 08/07/2007	Recruitment status Stopped	<input type="checkbox"/> Prospectively registered
Registration date 21/08/2007	Overall study status Stopped	<input type="checkbox"/> Protocol
Last Edited 07/02/2012	Condition category Urological and Genital Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Donna Greenhalgh

Contact details

Consultant Anaesthetist
Wythenshawe Hospital
South Moore Road
Wythenshawe
Manchester
United Kingdom
M23 9LT
+44 (0)161 291 2525
donna.greenhalgh@btopenworld.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

07/Q1403/17

Study information

Scientific Title

Acronym

N-Acetylcysteine prophylaxis for onpump CABG

Study objectives

Prohylatic use of N-Acetylcysteine will decrease the incidence of renal failure in patients undergoing onpump Coronary Artery Bypass Graft (CABG) surgery.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved by South Manchester Research Ethics Committee (UK) on the 18th June 2007 (REC ref 07/Q1403/17).

Study design

Prospective randomised double blind controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Renal impairment

Interventions

For both groups, there will be no change in routine anaesthetic/surgical or post operative management.

The intervention group will be administered 2 g N-Acetylcysteine on the night before surgery (oral), 2 g at induction of anaesthesia (intravenous [IV]) and 2 g IV on the morning of first post operative day. The control group will receive placebos at the same time as the intervention group.

Patients will be followed up until discharge.

As of 07/02/2012, the trial was stopped in September 2010 due to problems with recruitment and the delay resulted in the trial being out of date.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

N-Acetylcysteine (Parvolex®)

Primary outcome measure

Creatinine clearance and serum creatinine levels on second and fifth post operative day and on discharge.

Secondary outcome measures

Length of Intensive Care Unit (ICU) stay.

Overall study start date

01/08/2007

Completion date

31/07/2008

Reason abandoned (if study stopped)

"Participant recruitment issue"

Eligibility

Key inclusion criteria

1. Patients undergoing elective coronary artery bypass surgery (onpump) at Wythenshawe Hospital
2. Aged 21 - 80 years

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

224 (112 in each group) (Trial stopped in September 2010)

Key exclusion criteria

1. Urgent or emergency cases
2. History of hypersensitivity to N-Acetylcysteine
3. Patients already taking N-Acetylcysteine
4. Patients with renal failure

Date of first enrolment

01/08/2007

Date of final enrolment

31/07/2008

Locations**Countries of recruitment**

England

United Kingdom

Study participating centre**Consultant Anaesthetist**

Manchester

United Kingdom

M23 9LT

Sponsor information**Organisation**

University Hospital of South Manchester NHS Foundation Trust (UK)

Sponsor details

Department of Research and Development

Wythenshawe Hospital

South Moore Road

Wythenshawe

Manchester

England

United Kingdom

M23 9LT

+44 (0)161 291 5775

andrew.maines@manchester.ac.uk

Sponsor type

Hospital/treatment centre

Website

<http://www.smuht.nwest.nhs.uk/>

ROR

<https://ror.org/00he80998>

Funder(s)**Funder type**

Government

Funder Name

University Hospital of South Manchester NHS Foundation Trust (UK)

Results and Publications**Publication and dissemination plan**

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration